PT - JOURNAL ARTICLE AU - Solastie, Anna AU - Nieminen, Tuomo AU - Ekström, Nina AU - Nohynek, Hanna AU - Lehtonen, Lasse AU - Palmu, Arto A. AU - Melin, Merit TI - Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022 AID - 10.1101/2023.02.17.23286042 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.17.23286042 4099 - http://medrxiv.org/content/early/2023/02/23/2023.02.17.23286042.short 4100 - http://medrxiv.org/content/early/2023/02/23/2023.02.17.23286042.full AB - Studying the prevalence of SARS-CoV-2 specific antibodies (seroprevalence) allows assessing the impact of epidemic containment measures and vaccinations, as well as estimation of the number of infections regardless of viral testing. We assessed antibody-mediated immunity to SARS-CoV-2 induced by infections and vaccinations from April 2020 to December 2022 in Finland by measuring serum IgG to SARS-CoV-2 nucleoprotein (N-IgG) and spike glycoprotein from randomly selected 18-85-year-old subjects (n=9794). N-IgG seroprevalence remained at <7% until the last quartile (Q) of 2021. After the emergence of the omicron variant, N-IgG seroprevalence increased rapidly and was 31% in Q1/2022 and 54% in Q4/2022. Seroprevalence was highest in youngest age groups from Q2/2022 onwards. We estimated that 51% of the Finnish 18-85-year-old population had antibody-mediated hybrid immunity induced by a combination of vaccinations and infections by the end of 2022. In conclusion, major shifts in the COVID-19 pandemic and resulting population immunity could be observed by serological testing.Competing Interest StatementThe Finnish Institute for Health and Welfare (THL) has until 9/2022 conducted Public-Private Partnerships with vaccine manufacturers and has previously received research funding for studies unrelated to COVID-19 from GlaxoSmithKline Vaccines (N.E., A.A.P., and M.M. as investigators), Pfizer (A.A.P.), and Sanofi Pasteur (A.A.P., T.N.). M.M. and H.N. are members of the National Immunization Technical Advisory Group of THL. H.N. is chair of the WHO Strategic Advisory Group of Experts. The other authors report no potential conflicts of interest.Funding StatementThis study was funded by the Finnish Institute for Health and Welfare and the Academy of Finland (Decision number 336431).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participation was voluntary. The study protocol was approved by the ethical committee of the Hospital District of Helsinki and Uusimaa and registered under the study protocol HUS/1137/2020. Written Informed consent was obtained from all study subjects before sample collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and code are available from the corresponding author upon reasonable request.